Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent Pharma has appointed Kurt Nielsen as chief technology officer and senior vice president of innovation and growth, effective immediately. Dr Nielsen will have responsibility for driving innovation activities and investments across Catalent’s range of advanced dose forms and packaging technologies. He will report to John Chiminski, president and CEO of Catalent, and will be based in the global headquarters in Somerset, New Jersey.
Subscribe to our email newsletter
Dr Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical, where he lead new product development and licensing activities for both products and drug delivery technologies, as well as the division’s manufacturing and quality operations.
He had previously held the position of vice president of research and development at URLMutual. Dr Nielsen also held prior research and development leadership positions with Teva Pharmaceuticals USA and the McNeil Consumer Products division of Johnson & Johnson.
John Chiminski, president and CEO of Catalent, said: “We are excited to have Kurt join the Catalent executive team. Catalent’s foundation was built on proprietary technologies, and Kurt’s experience and leadership will accelerate and deepen our innovation activities for existing and new platforms. With his deep background in both pharmaceutical sciences and commercial activities, Kurt is uniquely suited to ensure we align our more than 1,000 scientists and engineers to produce the new innovations that both our customers and their patients need.”